Fig. 5

Glibenclamide and Abcc8−/− alter the cytokine profile in EAE. a–d White matter of lumbar spinal cord sections from WT control (a), untreated pid-30 WT/EAE (b), glibenclamide-treated pid-30 WT/EAE (c), and pid-30 Abcc8−/−/EAE (d) mice, immunolabeled for TNFα, IFN-γ, or IL-17, as indicated; original magnification, ×400. e Quantification of TNFα-, IFN-γ-, and IL-17-expressing cells in white matter; four mice/group; ^## P < 0.01 and ^### P < 0.001 with respect to WT control; *P < 0.05, **P < 0.01, and ***P < 0.001 with respect to WT/EAE; scale bars, 100 μm